AVN 64.60 Increased By ▲ 0.43 (0.67%)
BAFL 30.45 Increased By ▲ 0.55 (1.84%)
BOP 4.72 Increased By ▲ 0.09 (1.94%)
CNERGY 3.87 Decreased By ▼ -0.02 (-0.51%)
DFML 13.67 Increased By ▲ 0.32 (2.4%)
DGKC 41.25 Increased By ▲ 0.40 (0.98%)
EPCL 46.72 Decreased By ▼ -0.28 (-0.6%)
FCCL 11.13 Increased By ▲ 0.13 (1.18%)
FFL 5.10 Increased By ▲ 0.02 (0.39%)
FLYNG 5.88 Increased By ▲ 0.11 (1.91%)
GGL 9.96 Increased By ▲ 0.21 (2.15%)
HUBC 63.55 Increased By ▲ 1.60 (2.58%)
HUMNL 5.71 Increased By ▲ 0.06 (1.06%)
KAPCO 27.70 Increased By ▲ 0.12 (0.44%)
KEL 2.13 Decreased By ▼ -0.02 (-0.93%)
LOTCHEM 24.35 Increased By ▲ 0.05 (0.21%)
MLCF 21.15 Increased By ▲ 0.43 (2.08%)
NETSOL 84.94 Increased By ▲ 1.84 (2.21%)
OGDC 86.25 Increased By ▲ 0.20 (0.23%)
PAEL 11.05 Increased By ▲ 0.25 (2.31%)
PIBTL 4.18 Increased By ▲ 0.04 (0.97%)
PPL 76.25 Increased By ▲ 0.06 (0.08%)
PRL 13.69 Increased By ▲ 0.03 (0.22%)
SILK 0.89 No Change ▼ 0.00 (0%)
SNGP 40.90 Increased By ▲ 0.15 (0.37%)
TELE 5.90 Increased By ▲ 0.02 (0.34%)
TPLP 15.81 Increased By ▲ 0.16 (1.02%)
TRG 112.60 Increased By ▲ 2.50 (2.27%)
UNITY 14.00 Increased By ▲ 0.25 (1.82%)
WTL 1.14 Decreased By ▼ -0.01 (-0.87%)
BR100 4,016 Increased By 48.5 (1.22%)
BR30 14,321 Increased By 135.8 (0.96%)
KSE100 40,438 Increased By 567 (1.42%)
KSE30 15,094 Increased By 196 (1.32%)
World

J&J, Sinopharm, Sputnik V COVID-19 shots less effective against Omicron: study

  • Study was conducted by Humabs Biomed SA, a unit of Vir Biotechnology and the University of Washington, among others
Published December 17, 2021
Follow us

COVID-19 vaccines from US drugmaker Johnson & Johnson and China's Sinopharm as well as Russia's Sputnik V shot had no neutralizing activity against the Omicron variant, according to a study which has not yet been peer reviewed.

The Omicron variant has raised concerns regarding its ability to evade protection provided by widely-used vaccines, with drugmakers tailoring their shots to target the variant while testing the effectiveness of their existing shots.

Vaccines from Moderna, AstraZeneca and Pfizer and partner BioNTech retained activity against Omicron, but the antibody response was greatly reduced when compared with the original virus strain first detected in China, the study found.

WHO warns Covid variant Omicron risk ‘very high’

The study, conducted by Humabs Biomed SA, a unit of Vir Biotechnology and the University of Washington, among others, also found the decrease was less pronounced for vaccinated individuals who were previously infected.

The study also found that while the effectiveness of GlaxoSmithKline and Vir Biotech's COVID-19 drug sotrovimab reduced three-fold against Omicron compared to the original strain, monoclonal antibody treatments by Regeneron and Eli Lilly completely lost their neutralizing activity against the variant.

The finding is consistent with recent laboratory tests demonstrating the two treatments lose most of their effectiveness when exposed to the Omicron variant.

WHO sees unprecedented Omicron spread, 'probably' in most countries

In a real-world study published this week, it was seen that Pfizer-BioNTech's COVID-19 vaccine has been less effective in South Africa at keeping people infected with the virus out of hospital since the Omicron variant emerged last month.

Comments

Comments are closed.

J&J, Sinopharm, Sputnik V COVID-19 shots less effective against Omicron: study

Death toll in Peshawar mosque suicide blast passes 90

Dar meets IMF review mission, apprises it of planned power sector reforms

Intra-day update: rupee sees some improvement against US dollar

Intra-day update: Bull run at PSX, KSE-100 up over 750 points

Toshakhana case: Islamabad court decides to indict Imran Khan on February 7

Bangladesh secures $4.7bn from IMF as other South Asian countries see delays

Central banks bought the most gold since 1967 last year, WGC says

Talks with IMF team: Doubts exist about Dar-led team’s capability

Crucial IMF talks begin today

Alvi approves SOEs (Governance and Operations) Bill, 2022